High glucose and high insulin conditions promote MCF‑7 cell proliferation and invasion by upregulating IRS1 and activating the Ras/Raf/ERK pathway Corrigendum in /10.3892/mmr.2023.12967

Wei,Mei‑Lin; Duan,Peng; Wang,Zhi‑Ming; Ding,Miao; Tu,Ping

doi:10.3892/mmr.2017.7420

High glucose and high insulin conditions promote MCF‑7 cell proliferation and invasion by upregulating IRS1 and activating the Ras/Raf/ERK pathway

Corrigendum in: /10.3892/mmr.2023.12967

Authors:
- Mei‑Lin Wei
- Peng Duan
- Zhi‑Ming Wang
- Miao Ding
- Ping Tu
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang Key Laboratory of Diabetes, Nanchang, Jiangxi 330009, P.R. China
Published online on: August 31, 2017 https://doi.org/10.3892/mmr.2017.7420
Pages: 6690-6696
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetes mellitus is associated with an increased risk of breast cancer, but the molecular mechanism underlying this association remains unclear. The aim of the present study was to investigate the effect of high glucose and high insulin conditions on MCF‑7 breast cancer cells and to elucidate the molecular mechanisms underlying these effects. High glucose and high insulin conditions resulted in increased viability, proliferation, and invasion in MCF‑7 cells compared with normal glucose and low insulin conditions. Reverse transcription‑quantitative polymerase chain reaction and western blot analyses revealed that insulin receptor substrate 1 (IRS1) was significantly upregulated following high glucose and high insulin treatment compared with normal glucose and low insulin conditions. Furthermore, high glucose and high insulin treatment increased the Ras family of proto‑oncogenes (Ras) and RAF1 proto‑oncogene (Raf‑1) protein expression, and activated the phosphorylation of extracellular signal‑regulated kinase (ERK) 1/2. These findings suggest that high glucose and high insulin conditions promoted the proliferation and invasion of MCF‑7 cells by upregulating IRS1 and activating the Ras/Raf/ERK pathway.

View Figures

View References

1	http://www.diabetesatlas.org/
2	American Diabetes Association, . Diagnosis and classification of diabetes mellitus. Diabetes Care. 33 Suppl 1:S62–S69. 2010. View Article : Google Scholar : PubMed/NCBI
3	DeFronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88:787–835, ix. 2004. View Article : Google Scholar : PubMed/NCBI
4	Vigneri P, Frasca F, Sciacca L, Pandini G and Vigneri R: Diabetes and cancer. Endocr Relat Cancer. 16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
5	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
6	Larsson SC, Mantzoros CS and Wolk A: Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 121:856–862. 2007. View Article : Google Scholar : PubMed/NCBI
7	Vona-Davis L and Rose DP: Type 2 diabetes and obesity metabolic interactions: Common factors for breast cancer risk and novel approaches to prevention and therapy. Curr Diabetes Rev. 8:116–130. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP and Perks CM: Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: The role of fatty acid synthase. Endocr Relat Cancer. 17:539–551. 2010. View Article : Google Scholar : PubMed/NCBI
9	Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR and Hux JE: The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 109:389–395. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN and Giordano SH: Obesity, diabetes and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol. 24:2506–2514. 2013. View Article : Google Scholar : PubMed/NCBI
11	Hou G, Zhang S, Zhang X, Wang P, Hao X and Zhang J: Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat. 137:807–816. 2013. View Article : Google Scholar : PubMed/NCBI
12	Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA, Molinolo AA, et al: Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res. 70:741–751. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gallagher EJ and LeRoith D: The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
14	Rostoker R, Abelson S, Bitton-Worms K, Genkin I, Ben-Shmuel S, Dakwar M, Orr ZS, Caspi A, Tzukerman M and LeRoith D: Highly specific role of the insulin receptor in breast cancer progression. Endoc-Relat Cancer. 22:145–157. 2015. View Article : Google Scholar
15	Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA and Manson JE: Nurses' Health Study: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes care. 26:1752–1758. 2003. View Article : Google Scholar : PubMed/NCBI
16	Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ and Sarcevic B: Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol. 229:161–173. 2005. View Article : Google Scholar : PubMed/NCBI
17	Rose DP and Vona-Davis L: The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr-Relat Cancer. 19:R225–R241. 2012. View Article : Google Scholar : PubMed/NCBI
18	Li Y, Wang K, Zou QY, Magness RR and Zheng J: 2,3,7,8-Tetrachlorodibenzo-p-dioxin differentially suppresses angiogenic responses in human placental vein and artery endothelial cells. Toxicology. 336:70–78. 2015. View Article : Google Scholar : PubMed/NCBI
19	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
20	Li Y, Wang K, Jiang YZ, Chang XW, Dai CF and Zheng J: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) inhibits human ovarian cancer cell proliferation. Cellular oncology (Dordrecht). 37:429–437. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wang K, Li Y, Jiang YZ, Dai CF, Patankar MS, Song JS and Zheng J: An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells. Cancer letters. 340:63–71. 2013. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Li Y, Zhao YJ, Zou QY, Zhang K, Wu YM, Zhou C, Wang K and Zheng J: Preeclampsia does not alter vascular growth and expression of CD31 and vascular endothelial cadherin in human placentas. J Histochem Cytochem. 63:22–31. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li HH, Zhao YJ, Li Y, Dai CF, Jobe SO, Yang XS, Li XF, Patankar MS, Magness RR and Zheng J: Estradiol 17β and its metabolites stimulate cell proliferation and antagonize ascorbic acid-suppressed cell proliferation in human ovarian cancer cells. Reprod Sci. 21:102–111. 2014. View Article : Google Scholar : PubMed/NCBI
25	Shaw LM: The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer. Cell Cycle. 10:1750–1756. 2011. View Article : Google Scholar : PubMed/NCBI
26	Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008. View Article : Google Scholar : PubMed/NCBI
27	Papa V and Belfiore A: Insulin receptors in breast cancer: Biological and clinical role. J Endocrinol Invest. 19:324–333. 1996. View Article : Google Scholar : PubMed/NCBI
28	Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciacca L, Goldfine ID and Vigneri R: Insulin receptors in breast cancer. Ann N Y Acad Sci. 784:173–188. 1996. View Article : Google Scholar : PubMed/NCBI
29	Hamanaka RB and Chandel NS: Targeting glucose metabolism for cancer therapy. J Exp Med. 209:211–215. 2012. View Article : Google Scholar : PubMed/NCBI
30	Bergmann U, Funatomi H, Kornmann M, Beger HG and Korc M: Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun. 220:886–890. 1996. View Article : Google Scholar : PubMed/NCBI
31	Chang Q, Li Y, White MF, Fletcher JA and Xiao S: Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: Therapeutic implications. Cancer Res. 62:6035–6038. 2002.PubMed/NCBI
32	Sisci D, Morelli C, Garofalo C, Romeo F, Morabito L, Casaburi F, Middea E, Cascio S, Brunelli E, Andò S and Surmacz E: Expression of nuclear insulin receptor substrate 1 in breast cancer. J Clin Pathol. 60:633–641. 2007. View Article : Google Scholar : PubMed/NCBI
33	Molloy CA, May FE and Westley BR: Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 275:12565–12571. 2000. View Article : Google Scholar : PubMed/NCBI
34	Mauro L, Salerno M, Panno ML, Bellizzi D, Sisci D, Miglietta A, Surmacz E and Andò S: Estradiol increases IRS1 gene expression and insulin signaling in breast cancer cells. Biochem Biophys Res Commun. 288:685–689. 2001. View Article : Google Scholar : PubMed/NCBI
35	Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK and Yee D: Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 13:787–796. 1999. View Article : Google Scholar : PubMed/NCBI
36	de Blaquiere GE, May FE and Westley BR: Increased expression of both insulin receptor substrates 1 and 2 confers increased sensitivity to IGF-1 stimulated cell migration. Endocr Relat Cancer. 16:635–647. 2009. View Article : Google Scholar : PubMed/NCBI
37	Cesarone G, Garofalo C, Abrams MT, Igoucheva O, Alexeev V, Yoon K, Surmacz E and Wickstrom E: RNAi-mediated silencing of insulin receptor substrate 1 (IRS1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells. J Cell Biochem. 98:440–450. 2006. View Article : Google Scholar : PubMed/NCBI
38	Dearth RK, Cui X, Kim HJ, Kuiatse I, Lawrence NA, Zhang X, Divisova J, Britton OL, Mohsin S, Allred DC, et al: Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS1) or IRS-2. Mol Cell Biol. 26:9302–9314. 2006. View Article : Google Scholar : PubMed/NCBI
39	Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007. View Article : Google Scholar : PubMed/NCBI
40	Weng LP, Smith WM, Brown JL and Eng C: PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS1 phosphorylation and IRS1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet. 10:605–616. 2001. View Article : Google Scholar : PubMed/NCBI
41	Whyte J, Bergin O, Bianchi A, McNally S and Martin F: Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res. 11:2092009. View Article : Google Scholar : PubMed/NCBI
42	Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH and Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 80:239–256. 2002. View Article : Google Scholar : PubMed/NCBI
43	Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH and Murphy LC: Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res. 8:1747–1753. 2002.PubMed/NCBI